AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15747271 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 33
Study 15747271 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 33
Study 14671161 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment (6 microg/kg.d)
Number of subjects: 10
Study 14671161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10964832 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser entoptic perimetry
Number of subjects: 23
Study 10964832 — intervention group
Group type: COMPARATOR
Intervention: Achromatic threshold perimetry
Number of subjects: 23
Study 8997054 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of fentanyl 33 micrograms/ml with 0.17% bupivacaine
Number of subjects: 18
Study 8997054 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of morphine 0.21 mg/ml with 0.17% bupivacaine
Number of subjects: 18
Study 8997054 — intervention group
Group type: COMPARATOR
Intervention: Bolus epidural administration of fentanyl 100 micrograms
Number of subjects: 18
Study 8997054 — intervention group
Group type: COMPARATOR
Intervention: Bolus epidural administration of morphine 3 mg
Number of subjects: 18
Study 1430977 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 0
Study 1430977 — intervention group
Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 0
Study 2581855 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 24
Study 2581855 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (cyclophosphamide, vincristine and prednisone)
Number of subjects: 24
Study 30476976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone therapy for CSU
Number of subjects: 79
Study 28391886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 1257
Study 28391886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 1257
Study 28391886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257
Study 28391886 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (both dosages)
Number of subjects: 1257
Study 26883341 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 12
Study 26883341 — intervention group
Group type: COMPARATOR
Intervention: Standard supervised group-setting program
Number of subjects: 12
Study 25147733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - ten weekly intervention sessions
Number of subjects: 98
Study 25147733 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group) - nutritional support and education
Number of subjects: 98
Study 23065443 — intervention group
Group type: EXPERIMENTAL
Intervention: EUROACTION intervention programme
Number of subjects: 2024
Study 23065443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2024
Study 19160366 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique
Number of subjects: 164
Study 19160366 — intervention group
Group type: COMPARATOR
Intervention: Standard open insertion
Number of subjects: 164
Study 19160366 — intervention group
Group type: COMPARATOR
Intervention: Standard open insertion (as a rescue strategy)
Number of subjects: 164
Study 17208600 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (LAVRI‐A1)
Number of subjects: 231
Study 17208600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 15827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m sulfur colloid
Number of subjects: 72
Study 15827399 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m MIBI
Number of subjects: 72
Study 11990923 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NPSV) using a helmet
Number of subjects: 33
Study 11990923 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (NPSV) using a facial mask
Number of subjects: 33
Study 10860031 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft (demineralized freeze-dried bone and doxycycline hyclate 4:1 by volume) with resorbable calcium sulfate barrier
Number of subjects: 7
Study 10860031 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement only
Number of subjects: 7
Study 10860031 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft with resorbable barrier
Number of subjects: 7
Study 7782724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 6.7 mmol L-1
Number of subjects: 1843
Study 7782724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 6.0 mmol L-1
Number of subjects: 1843
Study 7782724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 4.8 mmol L-1
Number of subjects: 1843
Study 7782724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) optimal cut-off value of 5.3 mmol L-1
Number of subjects: 1843
Study 7782724 — intervention group
Group type: COMPARATOR
Intervention: 2-h oral glucose tolerance test (OGTT)
Number of subjects: 1843
Study 2371368 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 2‐13 ng/ml
Number of subjects: 111
Study 2371368 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 13.1‐24 ng/ml
Number of subjects: 111
Study 2371368 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 24.1‐35 ng/ml
Number of subjects: 111
Study 2371368 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (all levels)
Number of subjects: 111
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion
Number of subjects: 9
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl infusion
Number of subjects: 9
Study 27415 — intervention group
Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 9
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: Various test solutions (distilled water, 0.9% NaCl, 1.8% NaCl, 3.6% NaCl, 0.1 N HCl, 0.2 N HCl)
Number of subjects: 9
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion with increased rate
Number of subjects: 9
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of intraluminal fluid
Number of subjects: 9
Study 27415 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of bolus injection
Number of subjects: 9
Study 30498908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal delivery of mesenchymal stromal cells
Number of subjects: 0
Study 30498908 — intervention group
Group type: COMPARATOR
Intervention: Growth factor-based therapies
Number of subjects: 0
Study 30498908 — intervention group
Group type: COMPARATOR
Intervention: Small molecule-based therapies
Number of subjects: 0
Study 27548030 — intervention group
Group type: EXPERIMENTAL
Intervention: Modular treatment (MATCH)
Number of subjects: 138
Study 27548030 — intervention group
Group type: COMPARATOR
Intervention: Community-implemented treatment (CIT)
Number of subjects: 138
Study 25433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention
Number of subjects: 1010
Study 25433653 — intervention group
Group type: COMPARATOR
Intervention: General health promotion
Number of subjects: 1010
Study 25433653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health assessment
Number of subjects: 1010
Study 25433653 — intervention group
Group type: COMPARATOR
Intervention: General health assessment
Number of subjects: 1010
Study 25112699 — intervention group
Group type: COMPARATOR
Intervention: IL9 gene expression in children with PA
Number of subjects: 30
Study 25112699 — intervention group
Group type: COMPARATOR
Intervention: Machine-learning classification using IL9
Number of subjects: 30
Study 25112699 — intervention group
Group type: COMPARATOR
Intervention: Intracellular cytokine staining for IL-9 and IL-5
Number of subjects: 30
Study 22229802 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (multi-ply cookware)
Number of subjects: 3
Study 22229802 — intervention group
Group type: COMPARATOR
Intervention: Group B (ordinary cookware)
Number of subjects: 3
Study 19054570 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 121
Study 19054570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 18158692 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-day pragmatic hamstring stretching program on one lower extremity
Number of subjects: 13
Study 18158692 — intervention group
Group type: COMPARATOR
Intervention: Control lower extremity (no stretching)
Number of subjects: 13
Study 15349137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (66 mg elemental iron)
Number of subjects: 8
Study 15349137 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC) (100 mg elemental iron)
Number of subjects: 8
Study 15349137 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (baseline)
Number of subjects: 8
Study 11332584 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625mg/day of CEE orally
Number of subjects: 8
Study 11332584 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25mg/day of CEE orally
Number of subjects: 8
Study 11332584 — intervention group
Group type: EXPERIMENTAL
Intervention: 50microg/day of transdermal 17beta‐estradiol
Number of subjects: 8
Study 11332584 — intervention group
Group type: COMPARATOR
Intervention: No hormonal treatment
Number of subjects: 8
Study 9434661 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (25 mg as zinc sulfate)
Number of subjects: 118
Study 9434661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (800 micrograms retinol palmitate)
Number of subjects: 118
Study 9434661 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg as zinc sulfate)
Number of subjects: 118
Study 9434661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 118
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (2 x 15 g)
Number of subjects: 11
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltitol (2 x 15 g)
Number of subjects: 11
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalt (2 x 15 g)
Number of subjects: 11
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol (5, 10, or 20 g)
Number of subjects: 11
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Isomalt (5, 10, or 20 g)
Number of subjects: 11
Study 7859694 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyols (2 x 15 g intake)
Number of subjects: 11
Study 2913680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 60
Study 2913680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal tablets (0.5 mg) intravaginally every 6 hours
Number of subjects: 60
Study 2913680 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (bed rest and observation)
Number of subjects: 60
Study 7402800 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula
Number of subjects: 93
Study 7402800 — intervention group
Group type: COMPARATOR
Intervention: Non-iron-fortified formula
Number of subjects: 93
Study 30627829 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive underwear (shaper)
Number of subjects: 89
Study 30627829 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 89
Study 30627829 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study 28126022 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 100
Study 28126022 — intervention group
Group type: COMPARATOR
Intervention: Online intervention
Number of subjects: 100
Study 25469821 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS) during physical testing
Number of subjects: 18
Study 25469821 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS)
Number of subjects: 18
Study 23507071 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar sealer (Aquamantys 6.0 bipolar sealer)
Number of subjects: 200
Study 23507071 — intervention group
Group type: COMPARATOR
Intervention: Standard monopolar electrocautery
Number of subjects: 200
Study 21599551 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 41
Study 21599551 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 41
Study 19295201 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (UK) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Number of subjects: 11
Study 19295201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pcb) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Number of subjects: 11
Study 17876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 101
Study 17876342 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 101
Study 15087045 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg cabergoline
Number of subjects: 80
Study 15087045 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg cabergoline
Number of subjects: 80
Study 11294800 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban (2 microgram/kg/min IV, adjusted to maintain aPTT 1.5 to 3.0 times baseline)
Number of subjects: 304
Study 11294800 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (historical control)
Number of subjects: 304
Study 9068520 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary sinus group (defibrillation electrodes in the right atrium and coronary sinus)
Number of subjects: 80
Study 9068520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery group (defibrillation electrodes in the right atrium and left pulmonary artery)
Number of subjects: 80
Study 9068520 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 80
Study 9068520 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 80
Study 8422596 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise disclosure of prognostic information by physicians
Number of subjects: 0
Study 8422596 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 0
Study 3758244 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan-salbutamol combination
Number of subjects: 108
Study 3758244 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan
Number of subjects: 108
Study 3758244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 12575602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (megestrol acetate and Chinese medicine)
Number of subjects: 106
Study 12575602 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate alone
Number of subjects: 106
Study 12575602 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 106
Study 31405927 — intervention group
Group type: COMPARATOR
Intervention: 2 mg of the D2 antagonist haloperidol
Number of subjects: 53
Study 28927869 — intervention group
Group type: EXPERIMENTAL
Intervention: initial combination therapy including prednisone
Number of subjects: 0
Study 28927869 — intervention group
Group type: EXPERIMENTAL
Intervention: including infliximab
Number of subjects: 0
Study 28927869 — intervention group
Group type: COMPARATOR
Intervention: sequential DMARD monotherapy
Number of subjects: 0
Study 28927869 — intervention group
Group type: COMPARATOR
Intervention: step-up combination therapy
Number of subjects: 0
Study 28531893 — intervention group
Group type: EXPERIMENTAL
Intervention: HTR3A and HTR3B gene markers
Number of subjects: 149
Study 25283471 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 10 mg once daily
Number of subjects: 184
Study 25283471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 22922604 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing soluble fiber, caffeine, and green tea catechins
Number of subjects: 0
Study 22922604 — intervention group
Group type: EXPERIMENTAL
Intervention: Beverage containing soluble fiber
Number of subjects: 0
Study 22922604 — intervention group
Group type: COMPARATOR
Intervention: Equal calorie control beverage
Number of subjects: 0
Study 22922604 — intervention group
Group type: COMPARATOR
Intervention: No-beverage control condition
Number of subjects: 0
Study 20108306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (melanoma 1.0 mm to 1.59 mm)
Number of subjects: 1110
Study 20108306 — intervention group
Group type: COMPARATOR
Intervention: Group B (melanoma > or = 1.6 mm to 2.0 mm)
Number of subjects: 1110
Study 20108306 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 1110
Study 20108306 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 1110
Study 17697248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 210
Study 17697248 — intervention group
Group type: EXPERIMENTAL
Intervention: K3
Number of subjects: 210
Study 17697248 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 210
Study 17697248 — intervention group
Group type: EXPERIMENTAL
Intervention: K3, Mtwo, ProTaper
Number of subjects: 210
Study 15659723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 320
Study 15659723 — intervention group
Group type: COMPARATOR
Intervention: Aspirin plus esomeprazole (80 mg aspirin daily + 20 mg esomeprazole twice daily)
Number of subjects: 320
Study 11856065 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced gait at 120 steps/min
Number of subjects: 44
Study 11856065 — intervention group
Group type: COMPARATOR
Intervention: Preferred gait speed
Number of subjects: 44
Study 11856065 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel-strike measure
Number of subjects: 44
Study 7485927 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 g/day for 5 days
Number of subjects: 38
Study 7485927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 2181673 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 39
Study 2181673 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 39
Study 375435 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 110
Study 375435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 31103018 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU via nasal spray)
Number of subjects: 48
Study 31103018 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 28317674 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 320
Study 28317674 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 320
Study 28317674 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 320
Study 25652239 — intervention group
Group type: EXPERIMENTAL
Intervention: Jean Rives (JR) technique
Number of subjects: 110
Study 25652239 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic TEP repair
Number of subjects: 110
Study 25652239 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (JR and TEP)
Number of subjects: 110
Study 23937007 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids combined with psychological counseling therapy
Number of subjects: 154
Study 23937007 — intervention group
Group type: COMPARATOR
Intervention: Counseling therapy only
Number of subjects: 154
Study 21251382 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine
Number of subjects: 204
Study 21251382 — intervention group
Group type: EXPERIMENTAL
Intervention: oxybutynin
Number of subjects: 204
Study 21251382 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study 18664310 — intervention group
Group type: EXPERIMENTAL
Intervention: Free fruit provision
Number of subjects: 2032
Study 18664310 — intervention group
Group type: COMPARATOR
Intervention: Control (no free fruit)
Number of subjects: 2032
Study 17537082 — intervention group
Group type: EXPERIMENTAL
Intervention: Green House (GH) model
Number of subjects: 120
Study 15167120 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I thyroid doses
Number of subjects: 321
Study 15167120 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 321
Study 15167120 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-lived radioiodines (132I, 133I, 135I) and radiotelluriums (131mTe, 132Te)
Number of subjects: 321
Study 11848001 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate orally the evening before, clear liquid diet and two Fleet enemas 1 hour before the procedure
Number of subjects: 0
Study 11848001 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate orally the evening before, clear liquid the day of the exam, and two Dulcolax suppositories the day of the exam
Number of subjects: 0
Study 11848001 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Fleet enemas
Number of subjects: 0
Study 9204088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Benzoyl peroxide
Number of subjects: 25
Study 9204088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Clindamycin phosphate
Number of subjects: 25
Study 9204088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Erythromycin
Number of subjects: 25
Study 9204088 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl peroxide alone
Number of subjects: 25
Study 9204088 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate alone
Number of subjects: 25
Study 9204088 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 25
Study 8435259 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 40
Study 8435259 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 40